Karriereverlauf von Matthew Fearer
Ehemalige bekannte Positionen von Matthew Fearer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Public Communications Contact | 01.02.2023 | 01.12.2023 |
| ACCELERON PHARMA INC. | Public Communications Contact | 01.01.2021 | 01.04.2022 |
Whitehead Institute for Biomedical Research
 Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA. | Public Communications Contact | - | 01.10.2016 |
Statistik
International
| Vereinigte Staaten | 4 |
Operativ
| Public Communications Contact | 3 |
Sektoral
| Health Technology | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Whitehead Institute for Biomedical Research
Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA. | Commercial Services |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
- Börse
- Insiders
- Matthew Fearer
- Erfahrung
